Ethyl 4-cyano-2-phenyl-2-pyridin-4-ylbutanoate | 945936-57-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Ethyl 4-cyano-2-phenyl-2-pyridin-4-ylbutanoate
• CAS: 945936-57-2
• 化学式: C₁₈H₁₈N₂O₂
• 分子量: 294.353
• InChiKey: DVLVCTALXDLFRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  63
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Ethyl 4-cyano-2-phenyl-2-pyridin-4-ylbutanoate 在 镍 氢气 作用下， 以 四氢呋喃 为溶剂， 生成 3-Phenyl-3-pyridin-4-ylpiperidin-2-one
  参考文献：
  名称：

  WO2007/90826

  摘要：

  公开号：
• 作为产物：
  描述：

  α-phenyl-4-pyridine acetic acid ethyl ester 、 丙烯腈 在 苄基三甲基氢氧化铵 作用下， 以 1,4-二氧六环 为溶剂， 反应 18.0h， 生成 Ethyl 4-cyano-2-phenyl-2-pyridin-4-ylbutanoate
  参考文献：
  名称：

  Synthesis and structure–activity relationship of benzetimide derivatives as human CXCR3 antagonists

  摘要：

  The synthesis and evaluation of benzetimide derivatives showing potent CXCR3 antagonism are described. Optimization of the screening hits led to the identification of more potent CXCR3 antagonists devoid of anti-cholinergic activity and identification of the key pharmacophore moieties of the series. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.115

文献信息

• WO2007/90826
  申请人：——

  公开号：——

  公开（公告）日：——
• Piperidine Derivatives as Cxcr3 Receptor Antagonists
  申请人：Coesemans Erwin

  公开号：US20090030039A1

  公开（公告）日：2009-01-29

  The present invention relates to a compound of formula (I) a N-oxide thereof, a pharmaceutically acceptable salt thereof, a stereochemically isomeric form thereof or a solvate thereof, wherein X represents N or CH; Y and Z each independently represent C(═O) or CH 2 provided that at least one of Y and Z represents C(═O); R 1 represents CH(R 4 )-aryl or CH(R 4 )-heteroaryl; R 2 represents aryl 2 or heteroaryl; R 3 represents hydrogen; C 1-4 alkylcarbonyl; C 1-6 alkyl optionally substituted with C 1-6 alkyloxy, C 1-6 alkylthio, C 1-6 alkyloxycarbonyl or aryl 1 ; provided that when Y and Z each represent C(═O), X represents CH, R 3 represents hydrogen, R 4 represents hydrogen, and R 2 represents unsubstituted pyridyl or phenyl optionally substituted with one halo or with one C 1-4 alkyloxy or with one or two C 1-4 alkyl, then aryl in the definition of R 1 is other than phenyl substituted with one halo or with one or two C 1-4 alkyl; and provided that when Y and Z each represent C(═O), X represents CH, R 3 represents hydrogen, and R 2 represents unsubstituted pyridyl or phenyl optionally substituted with one halo or with one C 1-4 alkyloxy or with one or two C 1-4 alkyl, then heteroaryl in the definition of R 1 is other than unsubstituted thienyl or unsubstituted pyridyl. The present invention also relates to the use of a compound of formula (I) for the manufacture of a medicament for preventing or treating a disease mediated through activation of the CXCR3 receptor; to processes for preparing the compounds of formula (I) and pharmaceutical compositions comprising them.
• Synthesis and structure–activity relationship of benzetimide derivatives as human CXCR3 antagonists
  作者：Jean-Pierre Bongartz、Mieke Buntinx、Erwin Coesemans、Bart Hermans、Guy Van Lommen、Jean Van Wauwe

  DOI：10.1016/j.bmcl.2008.07.115

  日期：2008.11

  The synthesis and evaluation of benzetimide derivatives showing potent CXCR3 antagonism are described. Optimization of the screening hits led to the identification of more potent CXCR3 antagonists devoid of anti-cholinergic activity and identification of the key pharmacophore moieties of the series. (c) 2008 Elsevier Ltd. All rights reserved.